Details for New Drug Application (NDA): 216966
✉ Email this page to a colleague
NDA 216966 describes ANGIOTENSIN LL ACETATE, which is a drug marketed by Gland and is included in one NDA. It is available from one supplier. Additional details are available on the ANGIOTENSIN LL ACETATE profile page.
The generic ingredient in ANGIOTENSIN LL ACETATE is angiotensin ii acetate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the angiotensin ii acetate profile page.
The generic ingredient in ANGIOTENSIN LL ACETATE is angiotensin ii acetate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the angiotensin ii acetate profile page.
Summary for 216966
| Tradename: | ANGIOTENSIN LL ACETATE |
| Applicant: | Gland |
| Ingredient: | angiotensin ii acetate |
| Patents: | 0 |
Pharmacology for NDA: 216966
| Physiological Effect | Vasoconstriction |
Medical Subject Heading (MeSH) Categories for 216966
Suppliers and Packaging for NDA: 216966
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ANGIOTENSIN LL ACETATE | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 216966 | ANDA | Gland Pharma Limited | 68083-553 | 68083-553-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68083-553-01) / 1 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) | ||||
| Approval Date: | Jun 3, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
